Abstract
Background: The concept of the muscle as a secretory organ, developed during the last decades, partially answers to the issue of how the crosstalk between skeletal muscle and distant tissues happens. The beneficial effects of exercise transcend the simple improved skeletal muscle functionality: systemic responses to exercise have been observed in distal organs like heart, kidney, brain and liver. Increasing data have accumulated regarding the synthesis, the kinetics of release and the biological roles of muscular cytokines, now called myokines. The most recent techniques have meaningfully improved the identification of the muscle cell secretome, but several issues regarding the extent of secretion from the muscle as well as the actions of the myokines remain unexplained.
Methods: The goal of this review is to provide an update about the secretory properties of skeletal muscle during and after an acute bout of exercise and after exercise training, showing the main experimental evidences, but also speculate about the possible therapeutic use of the physical training-induced circulating factors, especially in some categories of patients in which the baseline conditions are heavily damaged by one or more pathological conditions.
Results: studies on myokines are relatively recent, and to date most of the evidence available in humans has focused on the biological role of Il-6 during muscle contraction. Regarding to the myokines more recently identified, for example myostatin, fibroblast growth factor 21 (FGF21), secreted protein acidic and rich in cysteine (SPARC) or follistatin-like 1 some of these seem to be promising therapeutic agents, but our awareness about their potential benefits towards human health is only at the beginning.
Conclusion: for many of the myokines identified to date, the information available is limited and not enough to characterize precise functions and activities carried out by those in man. Several issues need to be addressed by future studies, tailored to ascertain accurately and surely the biological role and the therapeutic potential of some myokines.
Keywords: Myokines, acute exercise, exercise training, cytokines.
Current Pharmaceutical Design
Title:Are the Myokines the Mediators of Physical Activity-Induced Health Benefits?
Volume: 22 Issue: 24
Author(s): Domenico Di Raimondo, Antonino Tuttolomondo, Gaia Musiari, Caterina Schimmenti, Alessandra D’Angelo and Antonio Pinto
Affiliation:
Keywords: Myokines, acute exercise, exercise training, cytokines.
Abstract: Background: The concept of the muscle as a secretory organ, developed during the last decades, partially answers to the issue of how the crosstalk between skeletal muscle and distant tissues happens. The beneficial effects of exercise transcend the simple improved skeletal muscle functionality: systemic responses to exercise have been observed in distal organs like heart, kidney, brain and liver. Increasing data have accumulated regarding the synthesis, the kinetics of release and the biological roles of muscular cytokines, now called myokines. The most recent techniques have meaningfully improved the identification of the muscle cell secretome, but several issues regarding the extent of secretion from the muscle as well as the actions of the myokines remain unexplained.
Methods: The goal of this review is to provide an update about the secretory properties of skeletal muscle during and after an acute bout of exercise and after exercise training, showing the main experimental evidences, but also speculate about the possible therapeutic use of the physical training-induced circulating factors, especially in some categories of patients in which the baseline conditions are heavily damaged by one or more pathological conditions.
Results: studies on myokines are relatively recent, and to date most of the evidence available in humans has focused on the biological role of Il-6 during muscle contraction. Regarding to the myokines more recently identified, for example myostatin, fibroblast growth factor 21 (FGF21), secreted protein acidic and rich in cysteine (SPARC) or follistatin-like 1 some of these seem to be promising therapeutic agents, but our awareness about their potential benefits towards human health is only at the beginning.
Conclusion: for many of the myokines identified to date, the information available is limited and not enough to characterize precise functions and activities carried out by those in man. Several issues need to be addressed by future studies, tailored to ascertain accurately and surely the biological role and the therapeutic potential of some myokines.
Export Options
About this article
Cite this article as:
Di Raimondo Domenico, Tuttolomondo Antonino, Musiari Gaia, Schimmenti Caterina, D’Angelo Alessandra and Pinto Antonio, Are the Myokines the Mediators of Physical Activity-Induced Health Benefits?, Current Pharmaceutical Design 2016; 22 (24) . https://dx.doi.org/10.2174/1381612822666160429121934
DOI https://dx.doi.org/10.2174/1381612822666160429121934 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quantitative Coronary Angiography: Back to the Past
Recent Patents on Medical Imaging Peripheral Arterial Disease and Oxidative Stress
Vascular Disease Prevention (Discontinued) Potential Role of TRP Channels in Cough Hypersensitivity?
Current Respiratory Medicine Reviews Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology Editorial (Thematic Issues: Autoimmunity and Autoinflammation: Cardiovascular Drug Targets and Design)
Current Pharmaceutical Design Alkylglycerol Lipid Precursors: A Review of Therapeutic Strategies for Plasmalogen Replacement
Current Organic Chemistry Polymorphism Gln27Glu of β2 Adrenergic Receptors in Patients with Ischaemic Cardiomyopathy
Current Vascular Pharmacology Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry High-throughput Drug Repositioning for the Discovery of New Treatments for Chagas Disease
Mini-Reviews in Medicinal Chemistry Effects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence.
Current Vascular Pharmacology Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues
Endocrine, Metabolic & Immune Disorders - Drug Targets Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Interactive Effect of Combined Exposure to Active and Passive Smoking on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety Tandem Mass Tag (TMT) Quantitative Proteomic Analysis of Serum Exosomes in Cerebral Small-vessel Disease (CSVD) Patients With Depressive Symptoms
Current Neurovascular Research A Conceptual Framework of Comorbidity for Investigation in the Context of Psychiatric Disturbance
Current Psychiatry Reviews Histamine-Dependent and -Independent Hypersensitivity Reactions to Contrast Media: The Impact of Antihistamines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy Cardiovascular Disease and Diabetes in South Asians: The Twin Epidemic
Current Diabetes Reviews Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design